GENERAL BIOPHYSICS, LLC
Xenon gas inhalation therapy to modulate microglial function and treat Alzheimer's disease
- Sector
- Biotech
- Total capital
- $3.8M
- Federal grants
- $3.8M
- 6 awards · 2021–2025
- Rank in peer group#212 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 6 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in HealthyHuman Subjects$50K
- Federal grantHealth and Human S · Phase I · Xenon gas inhalation as a novel treatment for opioid withdrawal syndrome$400K
- Federal grantHealth and Human S · Phase II · Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects$1.2M
- Federal grantHealth and Human S · Phase II · Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects$1.3M
- Federal grantHealth and Human S · Phase I · Xenon gas treatment to modulate microglia in neurodegenerative diseases$314K
- Federal grantHealth and Human S · Phase I · Xenon gas treatment to modulate microglia in neurodegenerative diseases$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#212 · top 41%
- Linked publications#66 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 6- PendingInhalation SystemUSPTOApplication 19362824
- PendingGas Detection SystemUSPTOApplication 18947803
- PendingInhaled Xenon Therapy In Neurodegenerative DiseaseUSPTOApplication 17914061
Show all 6 patent records
- Inhalation SystemMay 28, 2026 · Application 19362824Pending
- Gas Detection SystemMay 15, 2025 · Application 18947803Pending
- Inhaled Xenon Therapy In Neurodegenerative DiseaseApr 20, 2023 · Application 17914061Pending
- Inhaled Xenon Therapy In Neurodegenerative DiseaseApplication PCTUS2021024234Pending
- Inhaled Xenon Therapy in Alzheimer's DiseaseApplication 63072765Pending
- Method for Treatment of Neurodegenerative DiseaseApplication 62994548Pending
Recent research by its founders
- Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy202512 cites
- Xenon gas (Xe) treatment to restore microglial functions in Alzheimer’s disease (AD)20230 cites
- Эффективность нового лекарственного средства ФС-1 В лечении экспериментального туберкулеза20150 cites
Related companies, and why
- COMPANION SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- TAXIS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- Phi Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- DiaMedica Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- DURAVAX INCSimilar federal contract value in Biotech · null in contracts
- NEW HORIZON BIOTECH INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .